Search Result

Results for "

anticancer chemotherapy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (3) Adenosine Deaminase (1) AMPK (3) Antibiotic (9) Apoptosis (15) AUTACs (1) Autophagy (13) Bacterial (10) DNA/RNA Synthesis (2) Endogenous Metabolite (3) Ferroptosis (1) Fluorescent Dye (3) Glutathione Peroxidase (1) HBV (3) HIF/HIF Prolyl-Hydroxylase (1) HIV (3) HSP (1) Isotope-Labeled Compounds (5) Microtubule/Tubulin (1) Mitophagy (8) mTOR (1) PD-1/PD-L1 (1) Proton Pump (1) Reactive Oxygen Species (ROS) (1) Reference Standards (3) STAT (1) Topoisomerase (11)
By Research Areas:	Cancer (27) Infection (10) Neurological Disease (3)

By Targets:

ADC Payload (3)

Adenosine Deaminase (1)

AMPK (3)

Antibiotic (9)

Apoptosis (15)

AUTACs (1)

Autophagy (13)

Bacterial (10)

DNA/RNA Synthesis (2)

Endogenous Metabolite (3)

Ferroptosis (1)

Fluorescent Dye (3)

Glutathione Peroxidase (1)

HBV (3)

HIF/HIF Prolyl-Hydroxylase (1)

HIV (3)

HSP (1)

Isotope-Labeled Compounds (5)

Microtubule/Tubulin (1)

Mitophagy (8)

mTOR (1)

PD-1/PD-L1 (1)

Proton Pump (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (3)

STAT (1)

Topoisomerase (11)

By Research Areas:

Cancer (27)

Infection (10)

Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13629

Etoposide 170+ Cited Publications VP-16; VP-16-213	Topoisomerase Autophagy Mitophagy Bacterial Apoptosis Antibiotic	Infection Cancer
Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy .

HY-15142

Doxorubicin hydrochloride Maximum Cited Publications 650 Publications Verification Hydroxydaunorubicin hydrochloride; ADR	Topoisomerase ADC Payload AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial Fluorescent Dye	Infection Cancer
Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .

HY-13630

Etoposide phosphate 170+ Cited Publications BMY-40481	Topoisomerase Bacterial Autophagy Apoptosis	Infection Neurological Disease Cancer
Etoposide phosphate (BMY-40481) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate is the phosphate ester proagent of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate induces cell cycle arrest, apoptosis, and autophagy.

HY-15142R

Doxorubicin hydrochloride (Standard) 5 Publications Verification Hydroxydaunorubicin hydrochloride (Standard); ADR (Standard)	Reference Standards Topoisomerase ADC Payload AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial Fluorescent Dye	Infection Cancer
Doxorubicin hydrochloride (Standard) is the analytical standard of Doxorubicin hydrochloride. This product is intended for research and analytical applications. Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .

HY-15142A

Doxorubicin Hydroxydaunorubicin	ADC Payload Antibiotic Bacterial Topoisomerase AMPK HIV Autophagy Mitophagy Apoptosis HBV Fluorescent Dye	Infection Cancer
Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy .

HY-19542

C6 Ceramide 3 Publications Verification C6-Cer; N-Hexanoylsphingosine	Apoptosis	Cancer
C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

HY-P2657

Verucopeptin	HIF/HIF Prolyl-Hydroxylase Proton Pump Endogenous Metabolite	Cancer
Verucopeptin is a potent HIF-1 (IC50=0.22 μM) inhibitor and decreases the expression of HIF-1 target genes and HIF-1α protein levels. Verucopeptin strongly inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Verucopeptin exhibits antitumor activity against multidrug resistance (MDR) cancers and can be used for cancer research.

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-13629R

Etoposide (Standard) 1 Publications Verification VP-16 (Standard); VP-16-213 (Standard)	Reference Standards Topoisomerase Autophagy Mitophagy Bacterial Apoptosis Antibiotic	Infection Cancer
Etoposide (Standard) is the analytical standard of Etoposide. This product is intended for research and analytical applications. Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy .

HY-114842

TDRL-551 1 Publications Verification	DNA/RNA Synthesis	Cancer
TDRL-551 is a potent replication protein A (RPA) inhibitor (IC₅₀ = 18 µM). TDRL-551 inhibits RPA-DNA interaction and increases the anti-cancer efficacy of Platinum (Pt)-based chemotherapy. TDRL-551 can be used for the research of cancer, such as non-small cell lung cancer (NSCLC) .

HY-155339

Anticancer agent 168	Apoptosis DNA/RNA Synthesis	Cancer
Anticancer agent 168 (compound d16) is a inhibitor of DNA2. Anticancer agent 168 induces apoptosis and cell-cycle arrest mainly at S-phase, and exhibits anticancer activities and overcomes chemotherapy resistance in mutp53-bearing cancers .

HY-103159

1-Deazaadenosine	Adenosine Deaminase	Cancer
1-Deazaadenosine is a potent Adenosine deaminase (ADA) inhibitor with a K_i value of 0.66 μM. 1-Deazaadenosine exhibits anti-cancer activities in vitro and has the potential to be a chemotherapy agent for lymphoproliferative disorders .

HY-15142AS1

Doxorubicin-13C,d3 TFA Hydroxydaunorubicin-13C,d3 TFA	Isotope-Labeled Compounds Antibiotic Endogenous Metabolite	Infection Cancer
Doxorubicin- ¹³C,d₃ TFA is the deuterium and ¹³C labeled Doxorubicin. Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stoppin

HY-P11053

A17 peptide	HSP	Cancer
A17 peptide is a Hsp70-targeting peptide. A17 peptide binds to the ATP-binding domains of Hsp70. A17 peptide specifically inhibits the chaperone activity, thereby increasing the cells' sensitivity to apoptosis induced by chemotherapeutic agents, such as Cisplatin (HY-17394). A17 peptide can be used for anticancer chemotherapy research, such multiple myeloma .

HY-13630A

Etoposide phosphate disodium BMY-40481 disodium	Topoisomerase Autophagy Apoptosis	Neurological Disease Cancer
Etoposide phosphate disodium (BMY-40481 disodium) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate disodium is the phosphate ester proagent of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate disodium induces cell cycle arrest, apoptosis, and autophagy.

HY-124582

NEO214 1 Publications Verification	Autophagy mTOR	Cancer
NEO214 is an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram (HY-16900) and perillyl alcohol (HY-N7000). It has anti-cancer activity and blood-brain barrier (BBB) permeability. Over sex. NEO214 prevents autophagy-lysosome fusion, thereby blocking autophagic flux and triggering glioma cell death. The process involves mTOR activation, andTFEB(Transcription Factor EB) aggregation. NEO214 inhibitionMacroautophagy/autophagy in glioblastoma cells has the potential to overcome chemotherapy resistance in glioblastoma .

HY-139211

Difluorinated Curcumin 3,4-Difluorobenzylidene curcumin	Reactive Oxygen Species (ROS)	Cancer
Difluorinated Curcumin (3,4-Difluorobenzylidene curcumin) is a fluorinated curcumin analog with high bioavailability and anticancer activity. Difluorinated Curcumin inhibits the self-renewal ability of tumor stem/stem-like cells, clonogenicity, invasiveness and angiogenesis of tumor cells. Difluorinated Curcumin also increases cell sensitivity to chemotherapy .

HY-W744243

Etoposide-d4 VP-16-d₄; VP-16-213-d₄	Isotope-Labeled Compounds Apoptosis Topoisomerase Bacterial Autophagy Mitophagy Antibiotic	Cancer
Etoposide-d₄ (VP-16-d₄; VP-16-213-d₄) is the deuterium labeled Etoposide (HY-13629). Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy .

HY-170837

STAT5-IN-3	STAT	Cancer
STAT5-IN-3 (Compound 14a) is a STAT5 inhibitor with anticancer activity. STAT5-IN-3 blocks the tyrosine phosphorylation of STAT5A/5B at the Y694/699 sites and significantly reduces the expression of STAT5B protein, thereby inhibiting downstream gene transcription and blocking the proliferation and survival of leukemia cells. Additionally, STAT5-IN-3 holds significant value in overcoming chemotherapy resistance .

HY-176220

GPX4-AUTAC	AUTACs Autophagy Glutathione Peroxidase Ferroptosis	Cancer
GPX4-AUTAC is a GPX4-targeting autophagy-mediated degrader (AUTAC). GPX4-AUTAC consists of an inhibitor ML162-yne (HY-153748), a degradation tag FBnG (HY-W073762) and a glycol linker (HY-W021401). GPX4-AUTAC promotes the ubiquitination of GPX4 by E3 ligase TRAF6, and enhances the binding with GPX4 and p62, leading to the selective autophagy-dependent degradation of GPX4. GPX4-AUTAC significantly induces ferroptosis and shows a potent anti-cancer activity in breast cancer cells, breast cancer-derived organoids (PDOs) and MDA-MB-231 tumor xenograft mice model, with potent synergistic effects when combined with Sulfasalazine (SAS) (HY-14655) or chemotherapy drugs (Paclitaxel (HY-B0015) or Cisplatin (HY-17394)) .

HY-14919A

Denibulin hydrochloride MN-029	Microtubule/Tubulin	Cancer
Denibulin (MN-029) hydrochloride is an anti-angiogenic agent with anticancer activity. It can cause rapid closure of blood vessels in solid tumors and lead to dose-dependent killing of tumor cells, effectively enhancing the antitumor effects of radiation and cisplatin chemotherapy .

HY-13629S

Etoposide-d3 VP-16-d₃; VP-16-213-d₃	Isotope-Labeled Compounds Topoisomerase Antibiotic Apoptosis Bacterial Autophagy Mitophagy	Infection Cancer
Etoposide-d3 (VP-16-d3) is the deuterium labeled Etoposide (HY-13629). Etoposide (VP-16) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy .

HY-13629S1

Etoposide-13C,d3 VP-16-¹³C,d₃; VP-16-213-¹³C,d₃	Isotope-Labeled Compounds Topoisomerase Autophagy Mitophagy Bacterial Apoptosis Antibiotic	Infection Cancer
Etoposide- ¹³C,d₃ is the ¹³C- and deuterium labeled Etoposide. Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy .

HY-13630R

Etoposide phosphate (Standard) BMY-40481 (Standard)	Reference Standards Topoisomerase Bacterial Autophagy Apoptosis	Infection Neurological Disease Cancer
Etoposide phosphate (Standard) is the analytical standard of Etoposide phosphate. This product is intended for research and analytical applications. Etoposide phosphate (BMY-40481) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate is the phosphate ester proagent of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate induces cell cycle arrest, apoptosis, and autophagy.

HY-143303

Anticancer agent 32	Apoptosis	Cancer
Anticancer agent 32 (compound 2g) is an anticancer agent. Anticancer agent 32 shows anticancer activities, affects cell cycle and induces cell apoptosis. Anticancer agent 32 can be used for the research of cancer .

HY-129976

Pemetrexed tromethamine (dihydrochloric) dihydrate	Endogenous Metabolite	Cancer
Pemetrexed tromethamine dihydrochloric dihydrate is a chemotherapy drug used to treat pleural mesothelioma and non-small cell lung cancer, exhibiting potent anti-cancer activity.

HY-W766368

C6 Ceramide-13C2,d2 C6-Cer-¹³C₂,d₂; N-Hexanoylsphingosine-¹³C₂,d₂	Isotope-Labeled Compounds Apoptosis	Cancer
C6 Ceramide- ¹³C₂,d₂ (C6-Cer- ¹³C₂,d₂) is the deuterium labeled and ¹³C-labeled C6 Ceramide (HY-19542). C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

Cat. No.	Product Name

HY-L169

Anti-Drug-Resistant Compound Library	639 compounds
Resistance refers to the decrease in the effectiveness of drugs in treating diseases or symptoms. Due to the increasing global antibiotic resistance, it may threaten our ability to treat common infectious diseases. Drug resistance is also the main cause of chemotherapy failure in malignant tumors. In approximately 50% of cases, drug resistance exists even before chemotherapy begins. There are many mechanisms of anticancer drug resistance, including increased protein expression that leads to drug removal, mutations in drug binding sites, recovery of tumor protein production, and pre-existing genetic heterogeneity in tumor cell populations. In addition, the issue of drug resistance seems to have affected the development of new anticancer drugs. Drug resistance may be caused by various conditions, such as mutations, epigenetic modifications, and upregulation of drug efflux protein expression. Overcoming multidrug resistance in cancer treatment is becoming increasingly important. MCE designs a unique collection of 639 anti-drug-resistant compounds. It is a good tool to be used for research on cancer and other diseases.

Anti-Drug-Resistant Compound Library

639 compounds

Resistance refers to the decrease in the effectiveness of drugs in treating diseases or symptoms. Due to the increasing global antibiotic resistance, it may threaten our ability to treat common infectious diseases. Drug resistance is also the main cause of chemotherapy failure in malignant tumors. In approximately 50% of cases, drug resistance exists even before chemotherapy begins. There are many mechanisms of anticancer drug resistance, including increased protein expression that leads to drug removal, mutations in drug binding sites, recovery of tumor protein production, and pre-existing genetic heterogeneity in tumor cell populations. In addition, the issue of drug resistance seems to have affected the development of new anticancer drugs. Drug resistance may be caused by various conditions, such as mutations, epigenetic modifications, and upregulation of drug efflux protein expression. Overcoming multidrug resistance in cancer treatment is becoming increasingly important.

MCE designs a unique collection of 639 anti-drug-resistant compounds. It is a good tool to be used for research on cancer and other diseases.

HY-L135

Cancer Stem Cells Compound Library	3,355 compounds
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on. Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment. MCE supplies a unique collection of 3,355 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

Cancer Stem Cells Compound Library

3,355 compounds

With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on.

Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment.

MCE supplies a unique collection of 3,355 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

Cat. No.	Product Name	Target	Research Area

HY-P2657

Verucopeptin	HIF/HIF Prolyl-Hydroxylase Proton Pump Endogenous Metabolite	Cancer
Verucopeptin is a potent HIF-1 (IC50=0.22 μM) inhibitor and decreases the expression of HIF-1 target genes and HIF-1α protein levels. Verucopeptin strongly inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Verucopeptin exhibits antitumor activity against multidrug resistance (MDR) cancers and can be used for cancer research.

HY-P11053

A17 peptide	HSP	Cancer
A17 peptide is a Hsp70-targeting peptide. A17 peptide binds to the ATP-binding domains of Hsp70. A17 peptide specifically inhibits the chaperone activity, thereby increasing the cells' sensitivity to apoptosis induced by chemotherapeutic agents, such as Cisplatin (HY-17394). A17 peptide can be used for anticancer chemotherapy research, such multiple myeloma .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13629

Etoposide 170+ Cited Publications VP-16; VP-16-213	Infection Monophenols Classification of Application Fields Sinopodophyllum hexandrum (Royle) Ying Lignans Phenols Phenylpropanoids Plants Berberidaceae Disease Research Fields Source Classification	Topoisomerase Autophagy Mitophagy Bacterial Apoptosis Antibiotic
Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy .

HY-15142

Doxorubicin hydrochloride Maximum Cited Publications 650 Publications Verification Hydroxydaunorubicin hydrochloride; ADR	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Anthraquinones Disease Research Fields Source Classification	Topoisomerase ADC Payload AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial Fluorescent Dye
Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .

HY-15142R

Doxorubicin hydrochloride (Standard) 5 Publications Verification Hydroxydaunorubicin hydrochloride (Standard); ADR (Standard)	Quinones Structural Classification Microorganisms Anthraquinones Source Classification	Reference Standards Topoisomerase ADC Payload AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial Fluorescent Dye
Doxorubicin hydrochloride (Standard) is the analytical standard of Doxorubicin hydrochloride. This product is intended for research and analytical applications. Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .

HY-15142A

Doxorubicin Hydroxydaunorubicin	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Anthraquinones Phenols Polyphenols Disease Research Fields Source Classification	ADC Payload Antibiotic Bacterial Topoisomerase AMPK HIV Autophagy Mitophagy Apoptosis HBV Fluorescent Dye
Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC₅₀s of 0.8 μM and 2.67 μM, respectively. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy .

HY-13629R

Etoposide (Standard) 1 Publications Verification VP-16 (Standard); VP-16-213 (Standard)	Structural Classification Monophenols Sinopodophyllum hexandrum (Royle) Ying Lignans Phenols Phenylpropanoids Plants Berberidaceae Source Classification	Reference Standards Topoisomerase Autophagy Mitophagy Bacterial Apoptosis Antibiotic
Etoposide (Standard) is the analytical standard of Etoposide. This product is intended for research and analytical applications. Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy .

Cat. No.	Product Name	Chemical Structure

HY-15142AS1

Doxorubicin-13C,d3 TFA
Doxorubicin- ¹³C,d₃ TFA is the deuterium and ¹³C labeled Doxorubicin. Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stoppin

HY-W744243

Etoposide-d4
Etoposide-d₄ (VP-16-d₄; VP-16-213-d₄) is the deuterium labeled Etoposide (HY-13629). Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy .

HY-13629S

Etoposide-d3
Etoposide-d3 (VP-16-d3) is the deuterium labeled Etoposide (HY-13629). Etoposide (VP-16) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy .

HY-13629S1

Etoposide-13C,d3
Etoposide- ¹³C,d₃ is the ¹³C- and deuterium labeled Etoposide. Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy .

HY-W766368

C6 Ceramide-13C2,d2

C6 Ceramide- ¹³C₂,d₂ (C6-Cer- ¹³C₂,d₂) is the deuterium labeled and ¹³C-labeled C6 Ceramide (HY-19542). C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

anticancer chemotherapy

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products